The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Chest pain (acute or subacute), lone or prominent
Publications
Chest pain in a 12-year-old girl with ulcerative colitis after therapy with mesalazine.
BMJ case reports. 2013;2013
Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: a case report.
Case reports in pediatrics. 2011;2011:524364
Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy.
World journal of gastroenterology. 2008;14(27):4400-2
Possible mesalamine-induced pericarditis: case report and literature review.
Pharmacotherapy. 2002;22(3):391-4
Mesalamine-induced chest pain: a case report.
The Canadian journal of cardiology. 2000;16(5):667-9
Mesalamine-associated pleural effusion with pulmonary infiltration.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1998;55(21):2304-5
Mesalazine toxicity.
BMJ (Clinical research ed.). 1994;308(6927):533-4